Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4421
Structure:
Synonyms:
1,4-Dihydro-1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid
1,4-Dihydro-1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-1,4-dihydro-7-methyl-4-oxo-
1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure [German]
1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxilic acid
1-Ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
1-ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-ca rboxylic acid
1-Ethyl-7-methyl-1,4-dihydro-1,8-naphthyridin-4-one-3-carboxylic acid
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
1-Ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
3-Carboxy-1-ethyl-7-methyl-1,8-naphthidin-4-one
3-Carboxy-1-ethyl-7-methyl-1,8-naphthyridin-4-one
3374-05-8
3374-05-8 (hydrochloride salt, anhydrous)
389-08-2
389-08-2 (FREE ACID)
5-25-07-00384 (Beilstein Handbook Reference)
AC1L1I4P
AC1Q310A
Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico
Acide 1-etil-7-metil-1,8-naftiridin-4-one-3-carbossilico [Italian]
Acide nalidixico
Acide nalidixico [Italian]
Acide nalidixique
Acide nalidixique [French]
Acide nalidixique [INN-French]
Acido nalidissico
Acido nalidissico [DCIT]
Acido nalidixico
Acido nalidixico [INN-Spanish]
Acidum nalidixicum
Acidum nalidixicum [INN-Latin]
AG-F-37245
AIDS-001989
AIDS-032293
AIDS001989
AIDS032293
AKOS000120074
BB_NC-2103
Betaxina
BIDD:GT0529
BPBio1_000125
BRD-K47886988-323-03-0
BRN 0750515
BSPBio_000113
BSPBio_001889
C05079
C12H12N2O3
CCG-39298
CCRIS 2365
CHEBI:100147
CHEMBL5
CPD000058264
Cybis
D00183
DB00779
DivK1c_000058
Dixiben
Dixinal
EINECS 206-864-7
Eucistin
HMS1921G10
HMS2092K04
HMS2232H24
HMS3259O13
HMS500C20
HMS561K17
HSDB 3241
IDI1_000058
Innoxalon
Jicsron
KBio1_000058
KBio2_001398
KBio2_003966
KBio2_006534
KBio3_001109
KBioGR_001333
KBioSS_001398
Kusnarin
Lopac0_000837
LS-72
Maybridge1_007101
MLS000028504
MLS001148578
MLS002303041
N-1200
N0490
N5035_SIAL
N8878_SIAL
NA
naladixic acid
Naldixic acid
Nalidic acid
Nalidicron
Nalidixan
Nalidixane
Nalidixate
Nalidixate Sodium
Nalidixic
Nalidixic acid
NALIDIXIC ACID & CRL8131
Nalidixic acid (JP15/USP/INN)
Nalidixic acid (JP16/USP/INN)
Nalidixic acid USP27
Nalidixic acid [USAN:BAN:INN:JAN]
Nalidixic acid [USAN:INN:BAN:JAN]
Nalidixic acid, NegGram, Nevigramon, Nalidixin, Uronidix
Nalidixic acid-Supplied by Selleck Chemicals
Nalidixin
Nalidixinic acid
Nalitucsan
Nalix
Nalurin
Narigix
Naxuril
NCGC00018181-01
NCGC00018181-02
NCGC00018181-03
NCGC00018181-04
NCGC00018181-05
NCGC00018181-06
NCGC00018181-07
NCGC00018181-08
NCGC00018181-09
NCGC00018181-10
NCGC00021730-03
NCGC00021730-04
NCGC00021730-05
NCGC00021730-06
NCGC00021730-07
NCI-C56199
NCI60_041807
NCIOpen2_004342
NegGram
NegGram (TN)
Negram
Nevigramon
Nicelate
NINDS_000058
NIX
Nogram
NSC-82174
NSC82174
NSC82174 (FREE ACID)
Oprea1_010545
Poleon
Prestwick0_000187
Prestwick1_000187
Prestwick2_000187
Prestwick3_000187
S2328_Selleck
SAM002554914
Sicmylon
SMR000058264
Sodium Nalidixic Acid, Monohydrate
SPBio_001579
SPBio_002034
Specifen
Specifin
SPECTRUM1500756
Spectrum2_001360
Spectrum3_000075
Spectrum4_000817
Spectrum5_001540
Spectrum_000918
SR-01000003086-4
STK735579
Unaserus
UNII-3B91HWA56M
UPCMLD-DP129
UPCMLD-DP129:001
Uralgin
Uriben
Uriclar
Urisal
Urodixin
Uroman
Uroneg
Uronidix
Uropan
VU0239598-6
wil 18,320
WIN 18,320
WIN 18320
WIN 183203
WIN-18320
Wintomylon
Wintron
WLN: T66 BN EV JNJ B2 DVQ I1
ZERO/002632
ATC-Codes:
Side-Effects:
Side-EffectFrequency
abdominal pain0
papilledema0
weakness0
paresthesia0
peripheral neuropathy0
pruritus0
psychosis0
stevens - johnson syndrome0
swelling0
thrombocytopenia0
erythema0
urticaria0
vertigo0
vomiting0
joint stiffness0
metabolic acidosis0
nerve palsy0
photosensitivity0
nausea0
leukopenia0
acidosis0
anaphylaxis0
hemolytic anemia0
angioedema0
arteriosclerosis0
arthralgia0
blistering0
convulsions0
diarrhea0
diplopia0
dizziness0
somnolence0
eosinophilia0
epilepsy0
erythema multiforme0
rash0
headache0
dizziness and vertigo0

Target

show target details
Uniprot ID:Q7VFP2_HELHP
Synonyms:
DNA gyrase
EC-Numbers:5.99.1.3
Organism:Helicobacter hepaticus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

7616959
RNA polymerase (rpoB) mutants selected for increased resistance to gyrase inhibitors in Salmonella typhimurium.. A B Blanc-Potard; E Gari; F Spirito; N Figueroa-Bossi; L Bossi (1995) Molecular & general genetics : MGG display abstract
Some rifampicin-resistance (RifR) mutations make bacteria slightly resistant to the gyrase inhibitors novobiocin (Nov) and nalidixic acid (Nal). This suggested that it might be possible to isolate rpoB mutants using either drug for positive selection. In an initial test, we confirmed the presence of Rif-resistant isolates among clones selected for Nov resistance. These mutants are also more resistant to Nal. In a subsequent experiment, we found that mutants selected for low-level resistance to Nal include isolates harboring mutations genetically linked to the rpoB locus; of two such mutants studied, one is temperature-sensitive for growth. These two mutants, which are only marginally affected in their response to Nov, are normally sensitive to Rif and thus might be representative of a new class of rpoB alleles. The Rif-resistant and Rif-sensitive rpoB alleles that increase resistance to gyrase inhibitors have one property in common: they all suppress, to varying degrees, the defect in his operon regulation (transcriptional deattenuation) caused by a gyrase defect or inhibition by novobiocin. To further analyse the transcription-supercoiling relationships in these mutants, we examined the ability of RNA polymerase to recruit gyrase activity during transcription. This was done by two independent approaches: (i) observing transcription-induced accumulation of hyper-negatively supercoiled plasmid DNA in a topA mutant background and (ii) measuring transcription-induced plasmid DNA cleavage in the presence of oxolinic acid. Results indicate that the rpoB alleles described in this study diminish the recruitment of gyrase activity by the transcription process. This property correlates with a decrease in the rate of transcription initiation.